Encouraging Drug Treatment Results Announced from the EQUALISE Study in People with Lupus Nephritis
Equillium, Inc. announced interim results from its Type B portion (the second part) of the two-phase 1b EQUALISE study, investigating the drug itolizumab for the treatment of lupus nephritis (LN) (lupus-related kidney disease). So far, the study has yielded encouraging data.
Study participants with LN were administered the drug every two weeks during a 24-week period. At follow-up, 83% of participants achieved a complete or partial clinical response to the drug, with 67% reaching more than 80% reduction in urine protein levels, suggesting that the kidney function may be improved due to the absence of inflammation.
Researchers will continue to study the drug and further updates are expected in mid-2023. LN is a serious complication of lupus. Finding new and effective treatment options for LN is critically important. Continue to follow the Lupus Foundation of America for updates on itolizumab and learn more about medications used to treat lupus.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.Subscribe Now